Holen Sie sich die Stockscreener-App
3.4141
1.85%
-0.0259
Schlusskurs vom Vortag:
$3.44
Offen:
$3.42
24-Stunden-Volumen:
720.93K
Relative Volume:
0.04
Marktkapitalisierung:
$1.83B
Einnahmen:
$66.41M
Nettoeinkommen (Verlust:
$-559.78M
KGV:
-2.8399
EPS:
-1.2022
Netto-Cashflow:
$-328.09M
1W Leistung:
-0.11%
1M Leistung:
+4.85%
6M Leistung:
-3.81%
1J Leistung:
-28.17%
1-Tages-Spanne:
$3.3601
$3.435
1-Wochen-Bereich:
$3.2901
$3.70
52-Wochen-Spanne:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.415 | 1.84B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
525.08 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.43 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.74 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.10 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - The Globe and Mail
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade - Stock Titan
RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn - StocksToTrade
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - tikr.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
RXRX Stock Steadies As AI Drug Platform Gains Traction And Cash Burn Tightens - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes - Stock Titan
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Recursion (NASDAQ: RXRX) CFO has 25,018 shares withheld for taxes - Stock Titan
Recursion Pharmaceuticals (RXRX) Slips 1.58% as Stock Holds Above Key $2.95 SupportTriple EMA - vinanet.vn
Recursion Pharmaceuticals (RXRX) Dips 1.42% to $3.12 as Key Support Holds at $2.96Wave Truncation - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - Yahoo Finance
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 - Moomoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Moomoo
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Sep 01 '26 |
Sale |
3.34 |
30,000 |
100,200 |
6,158,287 |
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):